Pemphigus Vulgaris: Clinical Aspects and Evidence‑Based Management
This June 2025 review in *Advances in Skin & Wound Care* by Geng & Sibbald examines pemphigus vulgaris (PV)—a rare, potentially life-threatening autoimmune blistering disorder—covering its presentation, diagnostic methods, and therapeutic strategies. :contentReference[oaicite:1]{index=1}
Key Highlights:
- Clinical Presentation: PV typically begins with painful oral mucosal erosions, followed by fragile flaccid skin blisters that rupture to form erosions. Disease onset is most common between ages 40–60. :contentReference[oaicite:2]{index=2}
- Diagnostic Approach: Confirmatory testing includes direct immunofluorescence demonstrating IgG and C3 deposits, and serologic detection of anti–desmoglein 1/3 antibodies. :contentReference[oaicite:3]{index=3}
- Risk & Prognosis: Untreated mortality rates range from 5–30%. Historically fatal, outcomes have dramatically improved with current immunosuppressive regimens. :contentReference[oaicite:4]{index=4}
- Therapeutic Strategies: Systemic corticosteroids remain foundational, often combined with steroid-sparing agents. Biologics like rituximab are becoming frontline options. :contentReference[oaicite:5]{index=5}
- Wound Care Considerations: Management involves careful use of non-adherent dressings, infection prevention, and interdisciplinary coordination akin to burn strategies. :contentReference[oaicite:6]{index=6}
This review offers wound care clinicians a concise yet comprehensive guide to identifying, diagnosing, and managing PV with up-to-date, evidence-based recommendations.
Read the full article in Adv Skin Wound Care.
Keywords:
pemphigus vulgaris,
autoimmune blistering,
immunofluorescence,
rituximab,
wound care dressings